Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.77 |
| ▸ | ITGAV | P06756 | 16/20 | 0.77 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.77 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.77 |
| ▸ | F2R | P25116 | 1/20 | 0.56 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534624 | 0.87 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5F2R | |
| SCHEMBL13344605 | 0.86 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL2899617 | 0.83 | ITGB3 (0.70) | ITGB3ITGAVITGA2BITGB5F2R | |
| SCHEMBL3536444 | 0.82 | ITGB3 (0.71) | ITGB3ITGAVITGA2BITGB5F2R | |
| SCHEMBL13344615 | 0.80 | ITGB3 (0.85) | ITGB3ITGAVITGA2BITGB5F2R | |
| SCHEMBL13344577 | 0.79 | ITGB3 (0.66) | ITGB3ITGAVITGA2BITGB5F2R | |
| SCHEMBL13344586 | 0.79 | ITGB3 (0.68) | ITGB3ITGAVITGA2BITGB5F2R | |
| SCHEMBL13369229 | 0.78 | ITGB3 (0.83) | ITGB3ITGAVITGA2BITGB5F2R | |
| SCHEMBL13344609 | 0.77 | ITGB3 (0.82) | ITGB3ITGAVITGA2BITGB5F2R | |
| SCHEMBL2902210 | 0.77 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB5F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718673-B2 | Isonipecotamides for the treatment of integrin-mediated disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-05-18 | — | — | US | claimed |
| EP-1133489-B9 | ISONIPECOTAMIDES FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1133489-B1 | ISONIPECOTAMIDES FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2005-07-27 | — | — | EP | claimed |
| US-7718673-B2 | Isonipecotamides for the treatment of integrin-mediated disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718673-B2 | Isonipecotamides for the treatment of integrin-mediated disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-05-18 | — | — | US | disclosed |